Glucagon-like peptide-1 receptor agonists and risk of diabetic retinopathy in type 2 diabetes: A systematic review and network meta-analysis of randomized clinical trials

RECOMMENDED

Retinal Diseases

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy

★ 3 Recommended by Prof. emer. Dr Josef Flammer, Faculty Member

Am J Ophthalmol

Shah J, Makwana B, Panchal K, Patel V, Patel T, Khadke S, Verma A, Vivekanandan S, Kong Y, Upadhyay J, Dani SS, Ramsey KM, Ganatra S, Ramsey DJ

doi: 10.1016/j.ajo.2026.04.021

COMMENTED

Retinal Diseases

Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Ophthalmol Retina

Hong AT, Lin F, Keenan JD, Stewart JM

doi: 10.1016/j.oret.2026.02.002

Retinal Diseases

Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial

JAMA Ophthalmol

Sasako T, Ueki K, Miyoshi K, Miyake K, Aoyama T, Okazaki Y, Ishizuka N, Yamauchi T, Noda M, Kadowaki T, J-DOIT3 Study Group

doi: 10.1001/jamaophthalmol.2025.3819

COMMENTED

Retinal Diseases

Early Worsening of Diabetic Retinopathy Following Initiation of Hybrid Closed-Loop/Automated Insulin Delivery Systems in Type 1 Diabetes: A Systematic Review and Structured Study-Level Synthesis

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Obes Metab

Anson M, Iqbal A, Azmi S, Weston P, Hughes L, Choudhury M, Hughes DM, Zheng Y, Burgess PI, Alam U

doi: 10.1111/dom.71084

Macular Diseases

Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration

JAMA Ophthalmol

Ahuja AS, Paredes AA 3rd, Young BK

doi: 10.1001/jamaophthalmol.2025.3821

RECOMMENDED

Retinal Diseases

Diabetic retinopathy in Sub-Saharan Africa: prevalence and regional variations from a systematic review and meta-analysis

★ 2 Recommended by Prof. emer. Dr Josef Flammer, Faculty Member

BMC Ophthalmol

Ismail MF, Khalafalla I, Sheck ZO, Isse SAS, Farah FA, Mohamed IA, Qarbote AI, Warsame AA, Salah NA, Mire AM, Mumin BA

doi: 10.1186/s12886-025-04589-5

COMMENTED

Macular DiseasesRetinal Diseases

Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Am J Ophthalmol

Murray M, Schifano F, Chiappini S, Corkery JM, Guirguis A

doi: 10.1016/j.ajo.2025.12.015

COMMENTED

Macular Diseases

Impact of Glucagon-like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Ophthalmol Retina

Joo JH, Zhao AH, Chalasani M, Allan KC, Rachitskaya AV

doi: 10.1016/j.oret.2025.12.014

Macular Diseases

Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapy

Ophthalmol Retina

Myers WK, Heath G, Rohrer B

doi: 10.1016/j.oret.2025.12.016

Related content

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy

Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes

Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial

Early Worsening of Diabetic Retinopathy Following Initiation of Hybrid Closed-Loop/Automated Insulin Delivery Systems in Type 1 Diabetes: A Systematic Review and Structured Study-Level Synthesis

Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration

Diabetic retinopathy in Sub-Saharan Africa: prevalence and regional variations from a systematic review and meta-analysis

Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database

Impact of Glucagon-like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center

Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapy